{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:23:13Z","timestamp":1782915793389,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.vaccine.2006.10.030","type":"journal-article","created":{"date-parts":[[2006,10,28]],"date-time":"2006-10-28T11:18:43Z","timestamp":1162034323000},"page":"1868-1876","source":"Crossref","is-referenced-by-count":41,"title":["Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses"],"prefix":"10.1016","volume":"25","author":[{"given":"Donald L.","family":"Fine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max L.","family":"Teehee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Terpening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy L.H.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janae L.","family":"Raetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale C.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.10.030_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.ento.49.061802.123422","article-title":"Venezuelan equine enchephalitis","volume":"49","author":"Weaver","year":"2004","journal-title":"Ann Rev Entomol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.10.030_bib2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/oxfordjournals.aje.a120942","article-title":"Antigenic variants of Venezuelan equine encephalitis: their geographical distribution and epidemiologic significance","volume":"89","author":"Young","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2006.10.030_bib3","series-title":"Medical aspects of chemical and biological warfare","first-page":"561","author":"Smith","year":"1997"},{"key":"10.1016\/j.vaccine.2006.10.030_bib4","first-page":"79","article-title":"Venezuelan equine encephalitis","volume":"18","author":"Johnson","year":"1974","journal-title":"Adv Vet Sci Comp Med"},{"issue":"1","key":"10.1016\/j.vaccine.2006.10.030_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0042-6822(91)90114-Q","article-title":"Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone","volume":"183","author":"Davis","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2006.10.030_bib6","first-page":"99","article-title":"A molecular genetic approach to the study of Venezuelan equine encephalitis virus pathogenesis","volume":"9","author":"Davis","year":"1994","journal-title":"Arch Virol Suppl"},{"issue":"1","key":"10.1016\/j.vaccine.2006.10.030_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/viro.1995.1458","article-title":"Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1","volume":"212","author":"Davis","year":"1995","journal-title":"Virology"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2006.10.030_bib8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0264-410X(01)00337-1","article-title":"Onset and duration of protective immunity to IA\/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice","volume":"20","author":"Hart","year":"2001","journal-title":"Vaccine"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2006.10.030_bib9","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1016\/S0264-410X(03)00328-1","article-title":"Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models","volume":"21","author":"Pratt","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.10.030_bib10","series-title":"Sixth annual conference on vaccine research (S9), May 5\u20137","article-title":"Evaluation of a genetically modified live attenuated vaccine for Venezuelan equine encephalitis","author":"Reed","year":"2003"},{"issue":"24","key":"10.1016\/j.vaccine.2006.10.030_bib11","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1016\/j.vaccine.2004.12.023","article-title":"Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent 1E strain of Venezuelan equine encephalitis virus","volume":"23","author":"Reed","year":"2005","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2006.10.030_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/infdis\/137.3.227","article-title":"Johnson KM enzootic and epizootic Venezuelan equine encephalomyelitis virus in horses infected by peripheral and intrathecal routes","volume":"137","author":"Dietz","year":"1978","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2006.10.030_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jmv.1890380414","article-title":"Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine","volume":"38","author":"Engler","year":"1992","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2006.10.030_bib14","series-title":"Venezuelan encephalitis: proceedings of the workshop symposium on Venezuelan encephalitis virus","first-page":"369","article-title":"Inactivated and live VEE vaccines\u2014a review","author":"McKinney","year":"1972"},{"issue":"3","key":"10.1016\/j.vaccine.2006.10.030_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/tera.1420360303","article-title":"TC-83 Venezuelan equine encephalitis exposure during pregnancy","volume":"36","author":"Casamassima","year":"1987","journal-title":"Teratology"},{"key":"10.1016\/j.vaccine.2006.10.030_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/tera.1420160317","article-title":"Venezuelan equine encephalitis","volume":"16","author":"Wenger","year":"1977","journal-title":"Teratology"},{"issue":"1","key":"10.1016\/j.vaccine.2006.10.030_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/AEM.27.1.150-153.1974","article-title":"Inactivated Venezuelan equine encephalomyelitis vaccine prepared from attenuated (TC-83 strain) virus","volume":"27","author":"Edelman","year":"1974","journal-title":"Appl Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2006.10.030_bib18","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/infdis\/140.5.708","article-title":"Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C84)","volume":"140","author":"Edelman","year":"1979","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2006.10.030_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2006.10.030_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/infdis\/128.3.271","article-title":"Experimental infection of horses with enzootic and epizootic strains of Venezuelan equine encephalomyelitis virus","volume":"128","author":"Walton","year":"1973","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.10.030_bib21","first-page":"731","article-title":"Safety and efficacy of an attenuated Venezuelan equine encephalomyelitis vaccine for use in equidae","volume":"159","author":"Spertzel","year":"1971","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2006.10.030_bib22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/oxfordjournals.aje.a121416","article-title":"Isolation of the vaccine strain of Venezuelan equine encephalomyelitis virus from mosquitoes in Louisiana","volume":"95","author":"Pederson","year":"1972","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2006.10.030_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0264-410X(96)00204-6","article-title":"Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB\/c, but not C3H\/HeN mice","volume":"15","author":"Hart","year":"1997","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2006.10.030_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4269\/ajtmh.2001.64.49","article-title":"Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice","volume":"64","author":"Ludwig","year":"2001","journal-title":"Am J Trop Med Hyg"},{"issue":"26","key":"10.1016\/j.vaccine.2006.10.030_bib25","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/S0264-410X(00)00042-6","article-title":"Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate","volume":"18","author":"Hart","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.10.030_bib26","unstructured":"Pifat DY, Vogel AP. Final report: neurovirulence safety testing in rhesus macaques of a new vaccine candidate (V3526) for Venezuelan equine encephalitis virus (VEE) protocol O98-02G. United States Army Medical Research Institute of Infectious Disease, Office of Product Development and Regulatory Affairs. 2000. p. 1\u201393."},{"issue":"5","key":"10.1016\/j.vaccine.2006.10.030_bib27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/030098589803500508","article-title":"Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H\/HeN and BALB\/c mice","volume":"35","author":"Steele","year":"1998","journal-title":"Vet Pathol"},{"issue":"6","key":"10.1016\/j.vaccine.2006.10.030_bib28","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4269\/ajtmh.1999.60.1041","article-title":"Limited potential for mosquito transmission of genetically engineered, live-attenuated Venezuelan equine encephalitis virus vaccine candidates","volume":"60","author":"Turell","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.10.030_bib29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(96)02275-1","article-title":"Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group","volume":"348","author":"Weaver","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2006.10.030_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4269\/ajtmh.1998.59.100","article-title":"Association of Venezuelan equine encephalitis virus subtype 1E with two equine epizootics in Mexico","volume":"59","author":"Oberste","year":"1998","journal-title":"Am J Trop Med Hyg"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06011297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06011297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T20:30:49Z","timestamp":1587241849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06011297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0264410X06011297"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.10.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}